Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-08T02:30:38.828Z Has data issue: false hasContentIssue false
  • English
  • Français

C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication

Published online by Cambridge University Press:  27 September 2016

Zhilu Xu ,
Xiang Zhang ,
Jennie Lau  and
Jun Yu
Zhilu Xu
Affiliation:
Institute of Digestive Disease and the Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, China
Xiang Zhang
Affiliation:
Institute of Digestive Disease and the Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, China
Jennie Lau
Affiliation:
Institute of Digestive Disease and the Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, China Faculty of Medicine, SHHO College, The Chinese University of Hong Kong, Hong Kong, China SAR
Jun Yu*
Affiliation:
Institute of Digestive Disease and the Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, China
*
*Corresponding author: Dr Jun Yu, Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China. Tel: (852) 37636099; Fax: (852) 21445330; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. Non-alcoholic steatohepatitis (NASH) is a more severe form of NAFLD and causes subsequent pathological changes including cirrhosis and hepatocellular carcinoma. Inflammation is the key pathological change in NASH and involves a series of cytokines and chemokines. The C-X-C motif chemokine 10 (CXCL10), which is known as a pro-inflammation chemokine, was recently proven to play a pivotal role in the pathogenesis of NASH. Hepatic CXCL10 is mainly secreted by hepatocytes and liver sinusoidal endothelium. By binding to its specific receptor CXCR3, CXCL10 recruits activated CXCR3+ T lymphocytes and macrophages to parenchyma and promotes inflammation, apoptosis and fibrosis. The circulating CXCL10 level correlates with the severity of lobular inflammation and is an independent risk factor for NASH patients. Thus, CXCL10 may be both a potential prognostic tool and a therapeutic target for the treatment of patients with NASH. The aim of this review is to highlight the growing advances in basic knowledge and clinical interest of CXCL10 in NASH to propagate new insights into novel pharmacotherapeutic avenues.

Type
Review
Information
Expert Reviews in Molecular Medicine , Volume 18 , 2016 , e16
Copyright
Copyright © Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Farrell, G.C., Wong, V.W.-S. and Chitturi, S. (2013) NAFLD in Asia–as common and important as in the West. Nature Reviews Gastroenterology and Hepatology 10, 307-318 Google Scholar
2. Zhu, J.-Z. et al. (2015) Prevalence of nonalcoholic fatty liver disease and economy. Digestive Diseases and Sciences 60, 3194-3202 CrossRefGoogle ScholarPubMed
3. Bugianesi, E. et al. (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123, 134-140 Google Scholar
4. Clark, J.M., Brancati, F.L. and Diehl, A.M. (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. American Journal of Gastroenterology 98, 960-967 CrossRefGoogle ScholarPubMed
5. Tiniakos, D.G., Vos, M.B. and Brunt, E.M. (2010) Nonalcoholic fatty liver disease: pathology and pathogenesis. Annual Review of Pathology 5, 145-171 Google Scholar
6. Tilg, H. and Moschen, A.R. (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836-1846 CrossRefGoogle Scholar
7. Wolfs, M.G.M. et al. (2015) Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity. Nutrition & Diabetes 5, e146-e147 Google Scholar
8. Zhang, X. et al. (2014) CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. Journal of Hepatology 61, 1365-1375 CrossRefGoogle Scholar
9. Zhang, X. et al. (2016) CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy. Journal of Hepatology 64, 160-170 Google Scholar
10. Charo, I.F. and Ransohoff, R.M. (2006) The many roles of chemokines and chemokine receptors in inflammation. The New England Journal of Medicine 354, 610-621 Google Scholar
11. Simpson, K.J. et al. (2003) Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles. Clinical Science 104, 47-63 Google Scholar
12. Epstein, F.H. and Luster, A.D. (1998) Chemokines — chemotactic cytokines that mediate inflammation. The New England Journal of Medicine 338, 436-445 Google Scholar
13. Luster, A.D. and Ravetch, J.V. (1987) Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). The Journal of Experimental Medicine 166, 1084-1097 Google Scholar
14. Ahmadi, Z., Arababadi, M.K. and Hassanshahi, G. (2013) CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus. Inflammation 36, 364-371 Google Scholar
15. Chen, L.-J. et al. (2013) CXC chemokine IP-10: a key actor in liver disease? Hepatology International 7, 798-804 Google Scholar
16. Rajeev Mehla, D.G. and Ayyavoo, V. (2012) Chemokine deregulation in HIV infection: role of interferon gamma induced Th1-chemokine signaling. Journal of Clinical &Cellular Immunology 2013, S7 Google Scholar
17. Clark-Lewis, I. et al. (2003) Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. The Journal of Biological Chemistry 278, 289-295 Google Scholar
18. Lasagni, L. et al. (2003) An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. The Journal of Experimental Medicine 197, 1537-1549 CrossRefGoogle ScholarPubMed
19. Erhardt, A. and Tiegs, G. (2010) Tolerance induction in response to liver inflammation. “Digestive Diseases (Basel, Switzerland)” 28, 86-92 Google Scholar
20. Dufour, J.H. et al. (2002) IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. Journal of Immunology 168, 3195-3204 Google Scholar
21. Jaruga, B. et al. (2004) IFN-γ/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. American Journal of Physiology - Gastrointestinal and Liver Physiology 287, G1044-G1052 Google Scholar
22. Wallace, A.E. et al. (2013) Trophoblast-induced changes in C-x-C motif chemokine 10 expression contribute to vascular smooth muscle cell dedifferentiation during spiral artery remodeling. “Arteriosclerosis, Thrombosis, and Vascular Biology” 33, e93-e101 Google Scholar
23. Ciesielski, C.J. et al. (2002) TNFalpha-induced macrophage chemokine secretion is more dependent on NF-kappaB expression than lipopolysaccharides-induced macrophage chemokine secretion. European Journal of Immunology 32, 2037-2045 3.0.CO;2-I>CrossRefGoogle ScholarPubMed
24. Ge, M.Q. et al. (2012) NK cells regulate CD8+ T cell priming and dendritic cell migration during influenza A infection by IFN-γ and perforin-dependent mechanisms. Journal of Immunology 189, 2099-2109 Google Scholar
25. Teijaro, J.R. et al. (2011) Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146, 980-991 CrossRefGoogle ScholarPubMed
26. Shields, P.L. et al. (1999) Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. Journal of Immunology 163, 6236-6243 CrossRefGoogle ScholarPubMed
27. Treacy, O. et al. (2012) Adenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation. PLoS ONE 7, e42662 Google Scholar
28. Hassanshahi, G. et al. (2007) Expression of CXC chemokine IP-10/Mob-1 by primary hepatocytes following heat shock. Saudi Medical Journal 28, 514-518 Google ScholarPubMed
29. Kanda, N. et al. (2007) IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. European Journal of Immunology 37, 338-350 Google Scholar
30. Fukui, A. et al. (2013) Interleukin-8 and CXCL10 expression in oral keratinocytes and fibroblasts via Toll-like receptors. Microbiology and Immunology 57, 198-206 Google Scholar
31. Phares, T.W. et al. (2013) Astrocyte-derived CXCL10 drives accumulation of antibody-secreting cells in the central nervous system during viral encephalomyelitis. Journal of Virology 87, 3382-3392 Google Scholar
32. Sarfo, B.Y. et al. (2011) Plasmodium berghei ANKA infection increases Foxp3, IL-10 and IL-2 in CXCL-10 deficient C57BL/6 mice. Malaria Journal 10, 69 Google Scholar
33. Albanesi, C. et al. (2000) IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines. Journal of Immunology 165, 1395-1402 Google Scholar
34. Maire, M. et al. (2008) Characterization of the double-stranded RNA responses in human liver progenitor cells. Biochemical and Biophysical Research Communications 368, 556-562 Google Scholar
35. Abe, T. et al. (2012) CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating, through an interaction with Toll-like receptor 2 and hyaluronan. Journal of Virology 86, 6159-6170 Google Scholar
36. Basset, L. et al. (2015) Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis. Journal of Molecular Medicine 93, 1355-1367 Google Scholar
37. Onabajo, O.O. et al. (2015) Expression of interferon lambda 4 is associated with reduced proliferation and increased cell death in human hepatic cells. Journal of Interferon & Cytokine Research 35, 150702121512000-150702121512900 Google Scholar
38. Kopydlowski, K.M. et al. (1999) Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. Journal of Immunology 163, 1537-1544 CrossRefGoogle ScholarPubMed
39. Vazirinejad, R. et al. (2014) The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis. Neuroimmunomodulation 21, 322-330 Google Scholar
40. Brownell, J. et al. (2014) Direct, interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during hepatitis C virus infection. Journal of Virology 88, 1582-1590 Google Scholar
41. Zeremski, M. et al. (2008) Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 48, 1440-1450 Google Scholar
42. Nishioji, K. et al. (2001) Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clinical Experimental Immunology 123, 271-279 CrossRefGoogle ScholarPubMed
43. Deng, G. et al. (2008) Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology 134, 716-726 Google Scholar
44. Lagging, M. et al. (2006) IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 44, 1617-1625 Google Scholar
45. Kimura, K. et al. (2002) Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. Journal of Immunology 169, 5188-5195 Google Scholar
46. Wasmuth, H.E. et al. (2009) Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 137, 309-319, 319.e301-319.e303Google Scholar
47. Holt, A.P. et al. (2009) Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology 136, 705-714 Google Scholar
48. Bonacchi, A. et al. (2001) Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. The Journal of Biological Chemistry 276, 9945-9954 CrossRefGoogle ScholarPubMed
49. Hintermann, E. et al. (2010) CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. Journal of Autoimmunity 35, 424-435 Google Scholar
50. Harvey, C.E. et al. (2003) Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. Journal of Leukocyte Biology 74, 360-369 Google Scholar
51. Leroux, A. et al. (2012) Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. Journal of Hepatology 57, 141-149 Google Scholar
52. Tosello-Trampont, A.-C. et al. (2012) Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. The Journal of Biological Chemistry 287, 40161-40172 CrossRefGoogle ScholarPubMed
53. Huang, W. et al. (2010) Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 59, 347-357 Google Scholar
54. Maina, V. et al. (2012) Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clinical Science 122, 545-553 Google Scholar
55. Odegaard, J.I. et al. (2008) Alternative M2 activation of Kupffer Cells by PPARδ Ameliorates obesity-induced insulin resistance. Cell Metabolism 7, 496-507 Google Scholar
56. Farrell, G.C. et al. (2012) NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut and Liver 6, 149-171 Google Scholar
57. Larter, C.Z. and Farrell, G.C. (2006) Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? 44, 253-261 Google Scholar
58. Harmon, R.C., Tiniakos, D.G. and Argo, C.K. (2014) Inflammation in nonalcoholic steatohepatitis. Expert Review of Gastroenterology & Hepatology 5, 189-200 Google Scholar
59. Mihm, S., Schweyer, S. and Ramadori, G. (2003) Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-γ and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. Journal of Medical Virology 70, 562-570 Google Scholar
60. Alkhouri, N. et al. (2012) Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver International 32, 297-302 Google Scholar
61. Kakimi, K. et al. (2001) Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. The Journal of Experimental Medicine 194, 1755-1766 Google Scholar
62. Ganz, M. and Szabo, G. (2013) Immune and inflammatory pathways in NASH. Hepatology International 7 (Suppl 2), 771-781 CrossRefGoogle ScholarPubMed
63. Marra, F. and Tacke, F. (2014) Roles for chemokines in liver disease. Gastroenterology 147, 577-594.e571Google Scholar
64. Romero, A.I. et al. (2006) Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. The Journal of Infectious Diseases 194, 895-903 Google Scholar
65. Mühlbauer, M. et al. (2003) A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125, 1085-1093 Google Scholar
66. Kassel, K.M. et al. (2010) Monocyte chemoattractant protein-1 deficiency does not affect steatosis or inflammation in livers of mice fed a methionine–choline-deficient diet. Laboratory Investigation 90, 1794-1804 Google Scholar
67. Rull, A. et al. (2009) Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis. Cytokine 48, 273-279 Google Scholar
68. Wong, V.W.-S. et al. (2010) Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59, 969-974 Google Scholar
69. Tamimi, T.I. et al. (2011) An apoptosis panel for nonalcoholic steatohepatitis diagnosis. Journal of Hepatology 54, 1224-1229 Google Scholar
70. Leite, N.C. et al. (2009) Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver International 29, 113-119 CrossRefGoogle ScholarPubMed
71. Baker, R.G., Hayden, M.S. and Ghosh, S. (2011) NF-κB, inflammation, and metabolic disease. Cell Metabolism 13, 11-22 Google Scholar
72. Bertola, A. et al. (2010) Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS ONE 5, e13577 Google Scholar
73. Bigorgne, A.E. et al. (2008) Obesity-induced lymphocyte hyperresponsiveness to chemokines: a new mechanism of fatty liver inflammation in obese mice. Gastroenterology 134, 1459-1469 Google Scholar
74. Haukeland, J.W. et al. (2006) Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. Journal of Hepatology 44, 1167-1174 CrossRefGoogle ScholarPubMed
75. Surapaneni, K.M., Priya, V.V. and Mallika, J. (2014) Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced nonalcoholic steatohepatitis (NASH). European Review for Medical and Pharmacological Sciences 18, 2736-2741 Google Scholar
76. Abdelmegeed, M.A. et al. (2012) Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. Journal of Hepatology 57, 860-866 Google Scholar
77. Leclercq, I.A. et al. (2000) CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. Journal of Clinical Investigation 105, 1067-1075 Google Scholar
78. Chang, C.-C. et al. (2015) Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease. Nature Publishing Group 5, 10096 Google Scholar
79. Feldstein, A.E. et al. (2003) Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437-443 Google Scholar
80. Sahin, H. et al. (2013) Proapoptotic effects of the chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in hepatocytes. Hepatology 57, 797-805 Google Scholar
81. Sidahmed, A.M.E. et al. (2012) CXCL10 contributes to p38-mediated apoptosis in primary T lymphocytes in vitro. Cytokine 59, 433-441 Google Scholar
82. Tirotta, E., Ransohoff, R.M. and Lane, T.E. (2011) CXCR2 signaling protects oligodendrocyte progenitor cells from IFN-γ/CXCL10-mediated apoptosis. Glia 59, 1518-1528 Google Scholar
83. Tirotta, E. et al. (2012) IFN-γ-induced apoptosis of human embryonic stem cell derived oligodendrocyte progenitor cells is restricted by CXCR2 signaling. Stem Cell Research 9, 208-217 Google Scholar
84. Brunt, E.M. et al. (2009) Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 49, 809-820 Google Scholar
85. Ramón Bataller, D.A.B. (2005) Liver fibrosis. Journal of Clinical Investigation 115, 209-218 Google Scholar
86. Gressner, A.M. and Weiskirchen, R. (2006) Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. Journal of Cellular and Molecular Medicine 10, 76-99 Google Scholar
87. Berres, M.-L., Nellen, A. and Wasmuth, H.E. (2010) Chemokines as immune mediators of liver diseases related to the metabolic syndrome. “Digestive Diseases (Basel, Switzerland)” 28, 192-196 Google Scholar
88. Lee, U.E. and Friedman, S.L. (2011) Mechanisms of hepatic fibrogenesis. Best Practice & Research Clinical Gastroenterology 25, 195-206 Google Scholar
89. Tomita, K. et al. (2016) CXCL10-mediates macrophage, but not other innate immune cells-associated inflammation in murine nonalcoholic steatohepatitis. Scientific Reports 6, 28786Google Scholar
90. Myers, R.P., Fong, A. and Shaheen, A.A.M. (2008) Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver International 28, 705-712 Google Scholar
91. Papagianni, M., Sofogianni, A. and Tziomalos, K. (2015) Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World Journal of Hepatology 7, 638-648 Google Scholar
92. Shen, J. et al. (2012) Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Alimentary Pharmacology & Therapeutics 36, 1057-1066 Google Scholar
93. Schulthess, F.T. et al. (2009) CXCL10 impairs β cell function and viability in diabetes through TLR4 signaling. Cell Metabolism 9, 125-139 Google Scholar
94. Zaldivar, M.M. et al. (2012) The chemokine receptor CXCR3 limits injury after acute toxic liver damage. Laboratory Investigation 92, 724-734 Google Scholar
95. Morimoto, J. et al. (2004) CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. Journal of Immunology 173, 7017-7024 CrossRefGoogle ScholarPubMed
96. Christen, U. et al. (2003) Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. Journal of Immunology 171, 6838-6845 Google Scholar
97. Franciotta, D. et al. (2001) Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. Journal of Neuroimmunology 115, 192-198 Google Scholar
98. Martire, S. et al. (2016) A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients. Journal of Neuroimmunology 292, 34-39 Google Scholar
99. Ko, E.M. et al. (2014) Deletion of astroglial CXCL10 delays clinical onset but does not affect progressive axon loss in a murine autoimmune multiple sclerosis model. Journal of Neuroinflammation 11, 105 Google Scholar
100. Edvardsen, K. et al. (2015) Peripheral blood cells from patients with autoimmune Addison's disease poorly respond to Interferons in vitro, despite elevated serum levels of interferon-inducible Chemokines. Journal of Interferon and Cytokine Research 35, 759-770 Google Scholar
101. Jackson, J.A. et al. (2011) Urinary Chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. American Journal of Transplantation 11, 2228-2234 Google Scholar
102. Brightling, C.E. et al. (2005) The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. American Journal of Respiratory and Critical Care Medicine 171, 1103-1108 Google Scholar
103. Wang, J. et al. (2008) Expression of CXC chemokine IP-10 in patients with chronic hepatitis B. Hepatobiliary & Pancreatic Diseases International 7, 45-50 Google Scholar
104. Taub, D.D., Longo, D.L. and Murphy, W.J. (1996) Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues of human peripheral Blood lymphocytes-SCID mice. Blood 87, 1423-1431 Google Scholar
105. Wang, X. et al. (1996) Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. The Journal of Biological Chemistry 271, 24286-24293 Google Scholar